Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.62 |
| ▸ | PARP14 | Q460N5 | 7/20 | 0.61 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.61 |
| ▸ | PARP1 | P09874 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698026 | 0.89 | NAMPT (0.64) | NAMPTPARP14PARP10PARP1LMNA | |
| SCHEMBL27550709 | 0.85 | NAMPT (0.62) | NAMPTPARP14PARP10LMNATSHR | |
| SCHEMBL28023904 | 0.81 | NAMPT (0.58) | NAMPTLMNATSHRMAPK1MAPT | |
| SCHEMBL2760493 | 0.80 | NAMPT (0.53) | NAMPTLMNATSHRMAPK1MAPT | |
| SCHEMBL11889729 | 0.80 | NAMPT (0.68) | NAMPTLMNAMAPK1MAPTUSP2 | |
| SCHEMBL6694937 | 0.79 | ITGB3 (0.56) | CYP17A1CYP21A2CYP11B1 | |
| Hydrochloric Acid SCHEMBL6700195 | 0.78 | ITGB3 (0.55) | CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL6698110 | 0.78 | ALDH1A1 (0.55) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL20347007 | 0.78 | LMNA (0.67) | NAMPTLMNATSHRMAPK1MAPT | |
| SCHEMBL29482202 | 0.78 | L3MBTL1 (0.62) | NAMPTTSHRKDM4ESMN1; SMN2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | NAMPT 396/4885PARP14 2750/4885PARP10 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.